Side-by-side · Research reference

TestagenvsThymosin α-1

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-MechanisticHUMAN-REVIEWED11/41 cited

BPhase 3HUMAN-REVIEWED8/39 cited

Testagen

Bioregulator Peptide · Khavinson School

Lys-Glu-Asp-GlySequenceFedoreyeva 2011

NuclearLocalizationFedoreyeva 2011

TesticularTissue target

SQ · Abdomen · Cyclical

Thymosin α-1

Immune modulator · Approved (some countries)

1.6 mgPer doseIyer 2007

Phase 3Evidence levelIyer 2007 Camerini 2001

~2 hrHalf-life

SQ · 2× weekly · 6+ months for chronic indications

01Mechanism of Action

Parameter

Testagen

Thymosin α-1

Primary target

Testicular tissue; proposed nuclear DNA interaction

Toll-like receptor 9 (TLR9) + T-cell maturation pathwayCamerini 2001

Pathway

Nuclear penetration → DNA/oligonucleotide binding → gene expression modulation (bioregulator hypothesis)Fedoreyeva 2011

TLR9 activation → ↑ IFN-α + IL-2 + IFN-γ → enhanced T-cell function + dendritic cell maturationIyer 2007

Downstream effect

Proposed support for spermatogenesis and testicular function; mechanistic data limited to nuclear localization and DNA interactionFedoreyeva 2011

Restored T-cell function, improved viral clearance, anti-tumour adjuvant effectsIyer 2007

Feedback intact?

Unknown — no HPG axis data

—

Origin

Khavinson bioregulator school — isolated from testicular tissue peptide fractions

Synthetic 28-AA peptide identical to natural Tα-1 isolated from thymus extractCamerini 2001

Antibody development

—

02Dosage Protocols

Parameter

Testagen

Thymosin α-1

Typical protocol (anecdotal)

100–200 mcg / day

No published human dosing studies; derived from Russian bioregulator practice.

—

Frequency

Once daily or alternate days

2× weekly (Mon/Thu typical)

Cycle length

10–20 days on, 10–14 days off

Bioregulator tradition uses pulsed cycles; no controlled data.

—

Evidence basis

Animal mechanistic / in vitro onlyFedoreyeva 2011

Phase 3 + approved (35+ countries as Zadaxin)Iyer 2007

Route

Subcutaneous

—

Reconstitution

Sterile water or bacteriostatic saline

Sterile water for injection per vial label

Half-life

Unknown — likely minutes (short peptide)

~2 hours plasma; tissue effect days

Standard dose (HBV/HCV)

—

1.6 mg SQ 2× weekly × 6–12 monthsIyer 2007

Lower / starter dose

—

0.8 mg per injection

Duration

—

6–12 months for chronic indications

Timing

—

No specific time

04Side Effects & Safety

Parameter

Testagen

Thymosin α-1

Injection site reactions

Erythema, mild irritation (potential)

—

Systemic effects

Unknown — no human safety data

—

Hormonal impact

No published data on testosterone, LH, FSH effects

—

Long-term safety

Unknown — no long-term studies

—

Injection site reaction

—

Erythema, mild discomfort

GI symptoms

—

Rare nausea

Fatigue

—

Common during initial weeks

Fever / flu-like

—

Mild interferon-like response possible

Autoimmune

—

Theoretical risk; caution in active autoimmune disease

Cancer risk

—

No signal — used as adjuvant in oncology

Pregnancy / OB

—

Avoid

Absolute Contraindications

Testagen

·Active testicular malignancy

Thymosin α-1

·Pregnancy / breastfeeding
·Hypersensitivity to peptide
·Concurrent immunosuppressant therapy (transplant patients)

Relative Contraindications

Testagen

·Hormone-sensitive cancers (no data; theoretical caution)
·Pregnant or breastfeeding (no data)

Thymosin α-1

·Active autoimmune disease
·Severe immunocompromised state without supervision

05Administration Protocol

Parameter

Testagen

Thymosin α-1

1. Reconstitution

Add 1–2 mL sterile or bacteriostatic water to lyophilised vial. Swirl gently; do not shake. Solution should be clear.

Add 1 mL sterile water per 1.6 mg vial → 1.6 mg/mL.

2. Injection site

Subcutaneous — abdomen or thigh. Rotate sites daily. Use standard insulin syringe (27–31G).

SQ — abdomen, thigh, or upper arm. Rotate sites.

3. Timing

Morning or evening; no established optimal timing. Anecdotal preference: evening to align with circadian testosterone patterns.

2× weekly, e.g. Monday + Thursday.

4. Storage

Lyophilised: room temp, dark. Reconstituted: refrigerate 2–8 °C, use within 14–21 days if bacteriostatic water used.

Lyophilised: refrigerate. Reconstituted: refrigerate, use within 24 h.

5. Cycle protocol

10–20 days on, 10–14 days off. Bioregulator tradition uses pulsed exposure; rationale: prevent receptor/pathway desensitisation.

27–31G, 4–8 mm insulin syringe.